Cardinal Health Reports 8.9% Net Earnings Increase and 22.4% Revenue Growth in Latest Quarter

Cardinal Health, Inc. reported a net earnings increase of 8.9% for the three months ended September 30, 2025, reaching $454 million compared to $417 million in the same period last year. The company's total comprehensive income also rose to $450 million, up from $429 million in the prior year. Revenue for the quarter was $64.0 billion, a significant increase of 22.4% from $52.3 billion in the previous year, driven primarily by growth in the Pharmaceutical and Specialty Solutions segment, which saw revenues rise to $59.2 billion from $48.0 billion.

The company experienced notable changes in its financial position, with total assets increasing to $55.2 billion from $53.1 billion as of June 30, 2025. Current assets rose to $38.5 billion, bolstered by an increase in cash and equivalents to $4.6 billion from $3.9 billion. However, current liabilities also increased, reaching $40.3 billion, up from $38.9 billion, primarily due to higher accounts payable, which rose to $36.9 billion from $34.7 billion. Cardinal Health's shareholders' deficit widened slightly to $2.7 billion from $2.6 billion, reflecting ongoing investments and share repurchase activities.

Strategically, Cardinal Health has been active in expanding its portfolio through acquisitions. The company announced the acquisition of Solaris Health for approximately $1.9 billion, which is expected to enhance its Specialty Alliance platform. Additionally, Cardinal Health completed the acquisition of Advanced Diabetes Supply Group for $1.0 billion and a 73% ownership interest in GI Alliance for $2.8 billion earlier in the fiscal year. These acquisitions are anticipated to contribute positively to the company's revenue and operational capabilities in the healthcare sector.

Operationally, Cardinal Health reported a significant increase in segment profit, which rose to $879 million from $642 million year-over-year. The company also noted an increase in share-based compensation expenses, reflecting its ongoing commitment to employee incentives. The total employee headcount remained stable, with no significant changes reported. The company continues to focus on enhancing its market share and operational efficiency, particularly in its Pharma segment, which is critical to its overall growth strategy.

Looking ahead, Cardinal Health expressed optimism about its future performance, citing the expected contributions from recent acquisitions and ongoing operational improvements. The company anticipates continued revenue growth driven by its diversified product offerings and strategic initiatives aimed at expanding its market presence. However, it also acknowledged potential challenges related to market conditions and regulatory environments that could impact its operations.